Orthocell (ASX:OCC) has been granted a U.S. patent relating to its cell factory technology which produces native cartilage and bone active proteins.
This technology is one of the regenerative medicine company’s pipeline products and supports its existing tendon and cartilage regeneration products that are currently marketed.
The intellectual property is focused on the generation of ‘tissue specific’ growth factors for the regeneration of cartilage and bone and follows on from the Cell Factory work for the cartilage injuries that was announced by Orthocell in May last year.
Growth factors are an important stimulator of soft tissue and bone regeneration and have traditionally been extremely difficult to isolate from the “soup” of various growth factors and proteins that exist within the body.
The milestone is considered an important step in bringing value to Orthocell’s tissue regeneration portfolio for enhancing repair of bone, tendon and cartilage injuries.
More than 500,000 cartilage surgeries are undertaken in the U.S. each year and the use of growth factors to prevent or augment a portion of these surgeries represents an attractive market opportunity for Orthocell.
The patent will expire in 2027.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.